Provectus Therapeutics is a spin-off biotech company from CUHK developing AI Drug Screening Platform at Single Cell Level to study tumor heterogeneity and drug resistance for Precision Oncology Research, New Drug Development and Personalized Cancer Treatment. Our advanced AI platform enables scientists conduct multi-dimensional single cell analysis to identify hidden relationship between multi-omics (e.g. genomics, proteomics and transcriptomics) and drug resistance, which is crucially important in tumor analysis and clinical application. High throughput drug screening can be conducted on heterogeneous cell population to anticipate therapeutic outcomes before cancer treatment and anticancer efficacy at early stage of drug development.

2022

Biotech

Student Startup